Down syndrome (DS) is the major cause of intellectual disability in humans and it is estimated there are over 300,000 individuals with this genetic disorder in the United States. Virtually all DS individuals have sufficient neuropathology for a diagnosis of AD in their 40th year. However, dementia may not develop until up to a decade later and some people remain cognitively intact. Thus, we seek to follow a group of adults ranging in age from 20-40 years over a 5 year period of time to identify age and dementia-associated changes in cognition and in particular focus on frontal lobe function.
Our aims are four-fold.
Aim 1 will cognitively characterize a cohort of adults with DS and follow individuals for a period of 5 years.
Aim 2 will use magnetic resonance imaging to measure white matter integrity on an annual basis in longitudinally followed people.
Aim 3 will assay plasma drawn annually from the cohort and measure signaling protein changes to identify biomarkers of AD development and that are also correlated with cognition.
Aim 4 will study archived and new autopsy brain samples from DS adults to identify molecular pathways that change prior and during AD development. The outcomes of the proposed studies will contribute to the development of noninvasive biomarkers that will assist in early AD diagnosis in DS and monitor disease progression. Further, novel biomarkers that are mechanistically related to aging, AD neuropathology and dementia will also provide outcomes for the design of future therapeutic clinical trials to treat or prevent dementia in DS.

Public Health Relevance

The proposed study will identify new ways in which to detect Alzheimer disease (AD) in adults with Down syndrome (DS) by monitoring changes in cognitive function, measuring brain changes by magnetic resonance imaging and profiling patterns of proteins in the plasma. In parallel, autopsy studies of brain samples will help us to understand how noninvasive cognitive, imaging and blood measures reflect the development of AD in DS. Treatments for AD in DS will be more effective if the disease is detected early and identifying biomarkers will greatly facilitate the development of therapeutics.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Research Project (R01)
Project #
5R01HD064993-05
Application #
8518433
Study Section
Special Emphasis Panel (ZHD1-MRG-C (28))
Program Officer
Oster-Granite, Mary Lou
Project Start
2009-09-30
Project End
2014-08-31
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
5
Fiscal Year
2013
Total Cost
$426,047
Indirect Cost
$123,707
Name
University of Kentucky
Department
Other Health Professions
Type
Schools of Medicine
DUNS #
939017877
City
Lexington
State
KY
Country
United States
Zip Code
40506
Day, Ryan J; McCarty, Katie L; Ockerse, Kayla E et al. (2016) Proteolytic Cleavage of Apolipoprotein E in the Down Syndrome Brain. Aging Dis 7:267-77
Anderson-Mooney, Amelia J; Schmitt, Frederick A; Head, Elizabeth et al. (2016) Gait dyspraxia as a clinical marker of cognitive decline in Down syndrome: A review of theory and proposed mechanisms. Brain Cogn 104:48-57
Head, Elizabeth; Lott, Ira T; Wilcock, Donna M et al. (2016) Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology. Curr Alzheimer Res 13:18-29
Lin, A-L; Powell, D; Caban-Holt, A et al. (2016) (1)H-MRS metabolites in adults with Down syndrome: Effects of dementia. Neuroimage Clin 11:728-35
Tramutola, Antonella; Pupo, Gilda; Di Domenico, Fabio et al. (2016) Activation of p53 in Down Syndrome and in the Ts65Dn Mouse Brain is Associated with a Pro-Apoptotic Phenotype. J Alzheimers Dis 52:359-71
Wilcock, Donna M; Schmitt, Frederick A; Head, Elizabeth (2016) Cerebrovascular contributions to aging and Alzheimer's disease in Down syndrome. Biochim Biophys Acta 1862:909-14
Tramutola, Antonella; Di Domenico, Fabio; Barone, Eugenio et al. (2016) Poly-Ubiquitinylation Profile in Down Syndrome Brain before and after the Development of Alzheimer Neuropathology. Antioxid Redox Signal :
Wilcock, Donna M; Hurban, Jennifer; Helman, Alex M et al. (2015) Down syndrome individuals with Alzheimer's disease have a distinct neuroinflammatory phenotype compared to sporadic Alzheimer's disease. Neurobiol Aging 36:2468-74
Di Domenico, Fabio; Pupo, Gilda; Mancuso, Cesare et al. (2015) Bach1 overexpression in Down syndrome correlates with the alteration of the HO-1/BVR-a system: insights for transition to Alzheimer's disease. J Alzheimers Dis 44:1107-20
Swaminathan, Arun; Jicha, Gregory A (2014) Nutrition and prevention of Alzheimer's dementia. Front Aging Neurosci 6:282

Showing the most recent 10 out of 30 publications